To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves QVAR (Beclomethasone Dipropionate HFA) Inhalation Aerosol For The Treatment Of Asthma URL: http://www.pslgroup.com/dg/1E17CA.htm Doctor's Guide September 18, 2000
ST. PAUL, MN -- September 18, 2000 -- 3M Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted approval for QVAR™ (beclomethasone dipropionate HFA) Inhalation Aerosol for the treatment of asthma. QVAR, a unique aerosol metered dose inhaler (MDI) which contains beclomethasone dipropionate (BDP) in a solution and no chlorofluorocarbon (CFC) propellant, is the first inhaler designed to deliver smaller-particle-sized medication to the large, intermediate and small airways. This allows QVAR to control asthma at a lower dose than conventional CFC-containing BDP inhalers. New QVAR is indicated for the preventive management of asthma for people over the age of 12 and contains the safe and effective corticosteroid, beclomethasone dipropionate. "Both the large and small airways in the lungs play an important role in asthma, but current inhalers fail to deliver medication to the smallest airways. This new drug represents a potential breakthrough for patients with asthma," said Sally Wenzel, M.D., a leading Pulmonologist from the National Jewish Medical and Research Center in Denver, Colorado. The efficacy of inhaled corticosteroids for the treatment of asthma is well established, both nationally and internationally, with treatment guidelines recommending their use as first-line therapy.(1-7) Corticosteroids, such as QVAR, for the treatment of asthma are usually administered by inhalation through a metered dose inhaler. Recent studies have shown that, in contrast to CFC-beclomethasone dipropionate (CFC-BDP) inhalers, QVAR delivers more medication to the lungs, where it is needed, and deposits less in the throat.(4) With QVAR, approximately 50 percent of the drug is administered to the lungs. Clinical trials have shown QVAR to be effective to conventional BDP at a lower dose.(1,2,8,9) At recommended doses, QVAR was not associated with any clinically relevant systemic side effects in adults.(9) QVAR is the first CFC-free metered dose inhaler containing a corticosteroid. QVAR is a formulation of the anti-inflammatory drug BDP, which uses the ozone friendly propellant hydrofluoroalkane (HFA). All CFC-containing inhalers will eventually be phased out in the United States. Thus, QVAR is a CFC-free BDP that has been developed to meet this change. Common side effects associated with the use of QVAR and placebo in clinical trials include, but are not limited to, headache (12 percent and 9 percent, respectively) and pharyngitis (8 percent and 4 percent, respectively). QVAR is not a bronchodilator and is not indicated for rapid relief of bronchospasm. Caution: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information). References: 1. Busse WW, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215-1222. 2. Demedts M, et al. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract. 1999;53:331-338. 3. Goldin JG, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol. 1999;104:S258-S267. 4. Leach CL, et al. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353. 5. Hamid Q, et al. Respiratory pathophysiologic responses. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100:44-51. 6. Martin RJ. Small airway and alveolar tissue changes in nocturnal asthma. Am J Resp Crit Care Med. 1998;157:S188-S190. 7. Macklem PT. The physiology of small airways. Am J Resp Crit Care Med. 1998;157:S181-S183. 8. Matthys H, et al. Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 mcg day-1 delivered as an extrafine aerosol in adults with moderate asthma. Respir Med. 1998;92(suppl A):17-22. 9. Gross G, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mcg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mcg, for the treatment of moderate asthma. CHEST. 1999;115:343-351. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.